Profile data is unavailable for this security.
About the company
Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. It operates in two segments: bioprocess solutions and lab products and services. The bioprocess solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, filter technology for clarification, among others. The lab Products and Services segment provides instruments, consumables, and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation, and membrane filter systems for sterility testing of parenteral.
- Revenue in EUR (TTM)3.32bn
- Net income in EUR83.20m
- Incorporated1990
- Employees13.76k
- LocationSartorius AGOtto-Brenner-Str. 20GOETTINGEN 37079GermanyDEU
- Phone+49 5513080
- Fax+49 5 513083289
- Websitehttps://www.sartorius.com/
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 2.68m | 7.17% |
| Schroder Investment Management Ltd.as of 31 Aug 2024 | 1.48m | 3.96% |
| Impax Asset Management Ltd.as of 31 Oct 2024 | 1.04m | 2.77% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 863.73k | 2.31% |
| Allianz Global Investors GmbHas of 30 Sep 2024 | 603.20k | 1.61% |
| Baillie Gifford & Co.as of 31 Oct 2024 | 560.13k | 1.50% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 553.49k | 1.48% |
| Franklin Advisers, Inc.as of 07 Nov 2024 | 506.74k | 1.35% |
| Union Investment Privatfonds GmbHas of 31 Mar 2024 | 393.60k | 1.05% |
| BlackRock Asset Management Deutschland AGas of 08 Nov 2024 | 326.81k | 0.87% |
